Compare GSK plc (GSK) vs Hormel Foods Corp (HRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Hormel Foods Corp — how do they compare? GSK plc trades at $52.85 (market cap $101.34B), while Hormel Foods Corp trades at $25.71 (market cap $13.84B). The key difference: GSK plc is far larger — about 7.3× Hormel Foods Corp's market cap, and Hormel Foods Corp pays the higher dividend (4.65%). Which is the better fit depends on your goals.
| GSK | HRL | |
|---|---|---|
Market Cap | $101.34B | $13.84B |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $29.91 |
52-Week Low | $36.20 | $19.74 |
Enterprise Value | $121.95B | $15.84B |
Dividend Yield | 3.49% | 4.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Hormel Foods (HRL) trades at $25.76, up 3.87% today, with a bullish technical signal from moving averages. The company has beaten EPS estimates for three consecutive quarters, though net income margin declined to 3.82% in 2025. Recent news highlights its status as a Dividend King with 60 years of consecutive increases and strategic moves like selling its Brazilian Ceratti business to sharpen growth focus.
Outlook remains cautious with mixed analyst sentiment (20% buy, 57% hold) and a consensus target of $26.33. Opportunities include dividend reliability and operational streamlining, but risks involve margin pressure and competitive food industry dynamics. The stock offers value near multi-year lows but requires patience amid earnings volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Hormel Foods Corp
Hormel Foods is a protein-focused branded food company. Its brands include its namesake Hormel, Spam, Jennie-O, Dinty Moore, Applegate, Wholly Guacamole, and Skippy. The vast majority of the company's revenue is U.S.-based: 64% U.S. retail, 28% U.S. food service, and 8% international. By product type, in fiscal 2021, 23% of revenue was shelf-stable foods, 18% was poultry (branded and commodity), 55% was other perishable food, and 3% was other, primarily nutritional products. The company holds the number-one market position in shelf-stable meat, shelf-stable ready meals, pepperoni, natural/organic deli meat, and guacamole and the number-two position in turkey, bacon, chilled ready meals, and peanut butter.
Read more on HRL →
